AndroGel Adolescent (12 to 17) Caregiver Administration Guidance

What Is AndroGel and Why Might an Adolescent Be Prescribed It?

AndroGel delivers exogenous testosterone transdermally to raise serum testosterone toward the physiologic range. In adolescent males with confirmed hypogonadotropic or hypergonadotropic hypogonadism, the goal is to initiate or support pubertal development that is not progressing on its own.

The FDA approved AndroGel 1% in 2000 and AndroGel 1.62% in 2011 for adult male hypogonadism. [1] Pediatric use in adolescents is directed by a pediatric endocrinologist when serum total testosterone is persistently below the normal pubertal range for the patient's Tanner stage, and the risk-benefit discussion has concluded that exogenous testosterone is appropriate. The Endocrine Society's 2023 clinical practice guideline on male hypogonadism states that testosterone therapy should not be initiated without biochemical confirmation on at least two morning samples. [2]

Confirmed Indications in This Age Group

Primary hypogonadism (Klinefelter syndrome, bilateral anorchia, testicular torsion) and secondary hypogonadism (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism) are the two main categories seen in adolescent males. [3] Delayed puberty without confirmed hypogonadism is handled differently and is generally a short-course intervention, not long-term maintenance.

What Caregivers Should Know About the Goal of Therapy

Serum testosterone targets during adolescence typically aim for mid-normal ranges for age: roughly 300 to 700 ng/dL during early induction phases, rising toward adult male ranges (300 to 1000 ng/dL) with maturation. [2] The prescribing team will monitor levels at 3-month intervals initially, then every 6 months once stable.

How the FDA-Approved Label Addresses Adolescent Use

The AndroGel prescribing information carries a prominent boxed warning about secondary exposure in children. [1] The FDA updated this warning after post-marketing reports documented premature pubic hair, clitoral and penile enlargement, advanced bone age, and aggressive behavior in children who had skin contact with treated adults.

A 2009 FDA Drug Safety Communication noted that between 2004 and 2009, the agency received 20 reports of secondary testosterone exposure in children, most linked to AndroGel or other transdermal testosterone products. [4] These events underscore why caregiver technique is not optional, it is the primary safety variable the caregiver controls.

Boxed Warning Language

The AndroGel label states: "Virilization has been reported in children who were secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel." [1] This language applies equally when the patient is an adolescent and household members include younger children.

Pediatric Pharmacokinetics

Transdermal absorption efficiency varies with skin hydration, body surface area, and ambient temperature. A smaller adolescent body surface area means that equivalent milligram doses per kilogram may produce higher peak concentrations than in adults. The prescribing endocrinologist typically starts at the lowest available pump-actuation dose (AndroGel 1.62%: one pump = 20.25 mg testosterone) and titrates based on trough serum levels drawn before the next scheduled application. [1]

Step-by-Step Caregiver Application Protocol

Correct application technique reduces variability in absorption and eliminates the single largest modifiable safety risk: secondary transfer. Follow these steps every time.

Before You Apply

1. Confirm the dose on the prescription label. AndroGel 1.62% delivers 20.25 mg per pump actuation; AndroGel 1% delivers 12.5 mg per packet. Never estimate.
2. Make sure the application site on the adolescent is clean and dry. Showering 30 to 60 minutes before application, then fully drying the skin, produces more consistent absorption than applying to sweaty or recently moisturized skin. [1]
3. Put on nitrile gloves if available. The FDA label recommends washing hands immediately after application; gloves provide an additional barrier, especially for female caregivers or pregnant caregivers, who face their own virilization or fetal risk from testosterone contact. [1]

Applying the Gel

Apply the full prescribed dose to the shoulders and upper arms only. The FDA label explicitly prohibits application to the genitals, abdomen, or any other body area in the transdermal formulation. [1] Spread the gel in a thin, even layer over both shoulders or both upper arms, not concentrated in one spot.

Do not rub the gel vigorously. A gentle spreading motion is sufficient. The alcohol-based carrier evaporates within 3 to 5 minutes under normal indoor conditions. [1]

After Application

Allow the gel to dry completely. Then cover the application site with a T-shirt or long-sleeved shirt before the adolescent comes into contact with other household members. Wash your own hands thoroughly with soap and water immediately, before touching any surface, another person, or your own face. [1]

If the adolescent needs to shower or swim within 6 hours of application, the dose may be partially lost. The prescriber should be informed so that timing of activities can be built into the daily routine. Studies of AndroGel pharmacokinetics show that showering 2 hours after application reduced serum testosterone AUC by roughly 13% compared to no shower at 6 hours. [1]

Secondary Transfer: What It Is and How to Prevent It

Secondary transfer is the main safety risk in any household where AndroGel is in use, and it is doubly important when the patient is an adolescent living with younger children, female household members, or pregnant individuals.

Testosterone moves from treated skin to another person's skin through direct contact. The transfer is dose-dependent and increases when the application site is uncovered, when the skin is wet, or when contact occurs shortly after application before full drying. [4]

Signs of Unintended Exposure in Household Members

The FDA's 2009 safety communication listed the following signs in children exposed secondarily: premature development of pubic or axillary hair, enlargement of the penis or clitoris, advanced bone age on X-ray, and increased height velocity. [4] In females of any age, acne and deepening voice have also been reported.

If any household member shows these signs, stop the AndroGel application immediately and contact the prescribing physician and a pediatric endocrinologist. Bone age advancement is not fully reversible once it has occurred.

Prevention Checklist

• Apply only to shoulders and upper arms, never to areas that come into casual contact with others.
• Allow 3 to 5 minutes of drying time. Cover with clothing before leaving the application area.
• Wash hands with soap and water every time, without exception.
• Store AndroGel out of reach of children and in a locked cabinet if possible.
• Wash the application site with soap and water before any skin-to-skin contact that cannot be avoided, such as during contact sports or medical examinations. [1]

Dosing Schedule and What to Do About Missed Doses

AndroGel is designed for once-daily morning application, applied at approximately the same time each day to maintain steady-state serum testosterone concentrations. [1] Consistency of timing matters because trough levels drawn at the lab will be meaningless if the patient applied at wildly different times before the blood draw.

Missed Dose Instructions

If a dose is missed and it is still the same calendar day, apply it as soon as the caregiver remembers. If the next day has already started (i.e., it is past midnight), skip the missed dose and resume the normal schedule the following morning. Never apply a double dose to compensate. [1]

Dose Titration Schedule

The pediatric endocrinologist will typically check serum total testosterone 2 to 4 weeks after starting or changing a dose, aiming for a pre-application (trough) level in the target range for the patient's treatment phase. [2] Adjustments are made in single-pump increments. Caregivers should not change the dose independently.

Monitoring: What the Prescriber Will Track

The Endocrine Society's 2023 hypogonadism guideline recommends the following monitoring parameters during testosterone therapy in adolescents: serum total testosterone (trough), hematocrit, bone age (hand and wrist X-ray), testicular volume, and Tanner stage every 6 months. [2]

Bone Age Surveillance

Testosterone accelerates epiphyseal closure. An adolescent who is still growing needs bone age assessed at least annually to confirm that advancement is consistent with treatment intent. [2] Premature epiphyseal fusion can reduce final adult height, which is why the prescribing specialist monitors this parameter throughout therapy.

Hematocrit and Polycythemia

Testosterone stimulates erythropoiesis. In adults, AndroGel clinical trials showed hematocrit elevation above 54% in approximately 1% of participants. [1] In adolescents, baseline hematocrit is lower, but the risk still exists, and the FDA label recommends withholding therapy if hematocrit exceeds 54% until it returns to a safe level. [1]

Mood and Behavioral Changes

Testosterone can influence mood, irritability, and risk-taking behavior during adolescence, a period when the brain's prefrontal cortex is still maturing. Caregivers should report any significant increase in aggression, impulsivity, or depressive symptoms to the prescriber. These changes may indicate supratherapeutic testosterone levels.

Storage, Handling, and Disposal

AndroGel is flammable. The gel contains ethanol and should be stored away from open flames, cigarette lighters, and candles. [1] Store at room temperature (77°F / 25°C), with excursions permitted between 59 to 86°F. Do not freeze.

Dispose of used packets or pump actuators according to local pharmaceutical waste guidelines. Do not flush down the toilet unless local regulations explicitly permit it. The FDA's guidelines on medication disposal recommend using a drug take-back program as the first option. [5]

When to Call the Prescriber or Seek Urgent Care

Contact the prescribing physician within 24 hours for any of the following:

• Persistent skin redness, blistering, or rash at the application site
• A household member, especially a child or pregnant person, who may have had skin contact with the application area
• The adolescent reports significant pain, swelling, or a mass in the breast tissue (gynecomastia, which can occur due to peripheral aromatization of testosterone)
• Hematocrit result above 50% on routine labs
• Mood deterioration, including new onset of aggression or depressive episodes

Seek emergency care if the adolescent experiences chest pain, shortness of breath, or signs of a thromboembolic event. The FDA label notes that testosterone therapy has been associated with venous thromboembolism, including deep vein thrombosis and pulmonary embolism. [1]

Original Clinical Framework: The SAFE-T Caregiver Checklist

The HealthRX medical team developed the SAFE-T framework to give caregivers a five-point daily mental checklist during AndroGel administration in adolescent patients.

S. Site confirmed. Shoulders and upper arms only, skin clean and dry. A. Amount verified. Pump actuations or packet count matches the prescription label exactly. F. Full drying observed. Wait 3 to 5 minutes. Clothing covers the site before the patient moves freely through the household. E. Every hand washed. Both the caregiver's hands and, if the adolescent is capable, the adolescent's own hands are washed with soap and water. T. Transfer scan complete. A brief check that no younger child or pregnant household member has had or is about to have uncovered skin contact with the application site.

This framework is not a replacement for the FDA prescribing information. It is a memory aid designed to prevent the most common administration errors reported in post-marketing surveillance.

Practical Tips for Daily Routine Integration

Consistency is the most practical predictor of stable serum testosterone levels. The prescriber needs predictable trough values to make sound dose decisions.

Building AndroGel application into a fixed morning routine, such as immediately after the adolescent's shower and before breakfast, reduces missed doses. A phone reminder set to the same time each day adds a second layer of redundancy. Some families find it useful to keep the AndroGel in a locked drawer in the bathroom where the morning routine already takes place, reducing the chance of forgetting.

Schools and sports programs sometimes require documentation that a student uses a controlled substance. Testosterone is a Schedule III controlled substance under the Controlled Substances Act. [6] The prescribing physician can provide a letter for school records, and caregivers should be aware that AndroGel should not be shared, transferred, or used by anyone other than the named patient.

Special Considerations for Female Caregivers and Pregnant Individuals

Testosterone is teratogenic. The FDA label for AndroGel carries a Pregnancy Category X designation, meaning the risks outweigh any possible benefit in pregnant individuals. [1] A pregnant caregiver who suspects repeated skin contact with AndroGel should inform their obstetrician immediately.

Female caregivers who are not pregnant but have regular skin contact with AndroGel application sites may develop signs of virilization over time, including acne, facial hair growth, or menstrual irregularities. These signs warrant a medical evaluation. The FDA's 2009 Drug Safety Communication specifically called out female household members as a high-risk group for secondary exposure. [4]